PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified

Drug that targets the driver mutation proves effective in animal studies

2013-12-09
(Press-News.org) Contact information: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified Drug that targets the driver mutation proves effective in animal studies

NEW ORLEANS— In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology (ASH). The finding may open the way to clinical trials of the drug in Waldenstrom's patients whose tumor cells carry the mutation.

Waldenstrom's is a form of non-Hodgkin lymphoma diagnosed in 2,000 to 3,000 people in the United States each year. In 2011, researchers led by Steven Treon, MD, PhD, director of the Bing Center for Waldenstrom Research at Dana-Farber, and Zachary Hunter, showed that tumor cells in 90 percent of Waldenstrom's patients carry a specific gene mutation – the first time the disease had been traced to a particular genetic flaw. More recently, Treon reported 29 percent of a small group of Waldenstrom's patients had mutations in the gene CXCR4.

In a study to be presented at the ASH meeting, Irene Ghobrial, MD, director of the Michele & Stephen Kirsch Laboratory at Dana-Farber, and Aldo Roccaro, MD, PhD, also of Dana-Farber, and their colleagues examined samples of Waldenstrom's tumor cells from a far larger group of patients – 250 in all – and found that CXCR4 was indeed mutated in about 30 percent of them.

In experiments with laboratory cell samples, the researchers found that Waldenstrom's tumor cells with the CXCR4 mutation proliferated more quickly than those without the mutation.

In mice, Waldenstrom's cells spread further and faster if they carried the CXCR4 mutation than if they did not, metastasizing to the animals' liver, bone marrow, lymph nodes, kidney, and lungs. When researchers re-examined Waldenstrom's cells from human patients, they found that cells from patients with the most aggressive disease were the most likely to have CXCR4 mutations.

"These findings led us to hypothesize that the CXCR4 mutation drives the disease – that it spurs Waldenstrom's cells to grow, divide, and metastasize," Ghobrial said. When researchers treated Waldenstrom's-carrying mice with an antibody that targets the mutation, progression of the disease halted.

"We have now identified a specific mutation that drives this rare disease, as well as a potential drug capable of acting against it," Ghobrial remarked. "We hope this work can be a springboard to clinical trials of drugs for patients with Waldenstrom's."

The findings are especially important in light of another study presented at the ASH conference. In it, researchers led by Treon and Maria Lia Palomba, MD, of Memorial Sloan-Kettering Cancer Center, tested ibrutinib – a drug that blocks growth signals in Waldenstrom's cells – in 63 Waldenstrom's patients who had received at least one prior treatment.

When researchers examined the bone marrow of 34 patients who had taken ibrutinib for six months, they found that the amount of marrow impacted by Waldenstrom's had declined between 45 and 70 percent. Patients whose Waldenstrom's cells harbored the CXCR4 mutation, however, did not respond as well to the drug, suggesting that they could particularly benefit from an agent that targets that specific mutation.

"The results show that ibrutinib is very active and well tolerated in patients with relapsed or hard-to-treat Waldenstrom's," Treon remarked. "The discovery of CXCR4 mutations in Waldenstrom's is an important milestone, and provides a means to identify which patients are more likely to benefit from ibrutinib. Our findings also provide a framework for studying combinations of ibrutinib with CXCR4 inhibitors."



INFORMATION:

The co-lead author of the CXCR4 study is Antonio Sacco, of Dana-Farber. Co-authors are Patricia Maiso, PhD, Michele Moschetta, MD, and Yuji Mishima, PhD, of Dana-Farber; Cristina Jimenez and Ramon Garcia-Sanz of Hospital Clinico de Salamanca, in Salamanca, Spain; Michelle Kuhne, PhD, and Pina Cardarelli, Ph.D, of Bristol-Myers Squibb; and Jesus San Miguel, MD, PhD, of Hospital Clinico Universitario, Salamanca Spain.

The co-lead author of the ibrutinib study is Christina Tripsas, MA, of Dana-Farber. Co-authors are Guang Yang, PhD, Yang Cao, MD, Lian Xu, Zachary Hunter, Steven Cropper, Patrick Mostyn, Kirsten Meid, MPH, Diane Warren, Christopher Patterson, Jacob Laubach, MD, Claudia Paba-Prada, MD, Janet Kunsman, NP, Irene Ghobrial, MD, and Sandra Kanan, NP, of Dana-Farber; Gaurav Varma, MSPH, of Stanford University Medical Center; and Ranjana Advani, MD, Stanford University School of Medicine.

The CXCR4 study was supported by the NIH (1R 01F0003743), the International Waldenstrom's Macroglobulinemia Foundation, the Kirsch Lab for Waldenstrom's Macroglobulinemia, the Heje Fellowship for Waldenstrom's Macroglobulinemia and by Bristol Myers Squibb.

The ibrutinib study was supported by a research grant from Pharmacyclics Inc. Funding for the whole genome sequencing project which made the genomic discoveries possible was provided by the Peter Bing Fund for Waldenstrom's Macroglobulinemia, and the International Waldenstrom's Macroglobulinemia Foundation.



ELSE PRESS RELEASES FROM THIS DATE:

EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus

2013-12-09
EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) ...

Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells

2013-12-09
Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells Study finds that growing stem cells in lab before transplant boosts survival MAYWOOD, Il. - Donated umbilical cord blood contains stem cells that can save the lives of patients with ...

Pioneering path to electrical conductivity in 'tinker toy' materials to appear in Science

2013-12-09
Pioneering path to electrical conductivity in 'tinker toy' materials to appear in Science LIVERMORE, Calif.— Sandia National Laboratories researchers have devised a novel way to realize electrical conductivity in metal-organic framework (MOF) materials, a development ...

Study shows first link between altitude and concussion

2013-12-09
Study shows first link between altitude and concussion Athletes experience fewer concussions at higher elevations AURORA, Colo. (Dec. 9, 2013) – A new study shows that high school athletes playing at higher altitudes suffer fewer concussions than those closer ...

Inflammation in prostate may reduce cancer risk

2013-12-09
Inflammation in prostate may reduce cancer risk MANHASSET, NY – Doctors at the North Shore-LIJ Health System have discovered that increased inflammation in the prostate may predict reduced risk for prostate cancer. The findings are published online ...

Ovarian cancer discovery deepens knowledge of survival outcomes

2013-12-09
Ovarian cancer discovery deepens knowledge of survival outcomes 10-gene biomarker identified as a tool in evaluating diagnosis, potential response to treatment and overall prognosis LOS ANGELES (Dec. 9, 2013) – Researchers in the Women's Cancer Program at ...

REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials

2013-12-09
REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials Initial consensus recommendations for studies of NF appear in special supplement to Neurology Philadelphia, Pa. (December 9, 2013) - As potentially effective new treatments ...

Peaceful bumblebee becomes invasive

2013-12-09
Peaceful bumblebee becomes invasive Bombus terrestris invades South America Bumblebees look cute. They have a thick fur, fly somewhat clumsily and are less aggressive than honeybees or wasps. They are very much appreciated by farmers as keen pollen collectors. ...

Better preparedness against Tamiflu-resistant influenza viruses

2013-12-09
Better preparedness against Tamiflu-resistant influenza viruses Swedish researchers in Umeå and Uppsala have found that residues of the influenza drug Tamiflu in our environment can make the influenza virus in birds resistant. This can have serious ...

How 'good cholesterol' stops inflammation

2013-12-09
How 'good cholesterol' stops inflammation Researchers at the University Hospital and the University of Bonn have discovered a central molecular switch High-density lipoprotein (HDL), known colloquially as "good cholesterol", protects against dangerous deposits ...

LAST 30 PRESS RELEASES:

Family ties and firm performance: How cousin marriage traditions shape informal businesses in Africa

Novel flu vaccine adjuvant improves protection against influenza viruses, study finds

Manipulation of light at the nanoscale helps advance biosensing

New mechanism discovered in ovarian cancer peritoneal metastasis: YWHAB restriction drives stemness and chemoresistance

New study links blood metabolites and immune cells to increased risk of urolithiasis

Pyruvate identified as a promising therapeutic agent for ulcerative colitis by targeting cytosolic phospholipase A2

New insights into the clinical impact of IKBKG mutations: Understanding the mechanisms behind rare immunodeficiency syndromes

Displays, imaging and sensing: New blue fluorophore breaks efficiency records in both solids and solutions

Sugar, the hidden thermostat in plants

Personality can explain why some CEOs earn higher salaries

This puzzle game shows kids how they’re smarter than AI

Study suggests remembrances of dead played role in rise of architecture in Andean region

Brain stimulation can boost math learning in people with weaker neural connections

Inhibiting enzyme could halt cell death in Parkinson’s disease, study finds

Neurotechnology reverses biological disadvantage in maths learning

UNDER EMBARGO: Neurotechnology reverses biological disadvantage in maths learning

Scientists target ‘molecular machine’ in the war against antimicrobial resistance

Extending classical CNOP method for deep-learning atmospheric and oceanic forecasting

Aston University research: Parents should encourage structure and independence around food to support children’s healthy eating

Thunderstorms are a major driver of tree death in tropical forests

Danforth Plant Science Center adds two new faculty members

Robotic eyes mimic human vision for superfast response to extreme lighting

Racial inequities and access to COVID-19 treatment

Residential segregation and lung cancer risk in African American adults

Scientists wipe out aggressive brain cancer tumors by targeting cellular ‘motors’

Capturability distinction analysis of continuous and pulsed guidance laws

CHEST expands Bridging Specialties Initiative to include NTM disease and bronchiectasis on World Bronchiectasis Day

Exposure to air pollution may cause heart damage

SwRI, UTSA selected by NASA to test electrolyzer technology aboard parabolic flight

Prebiotics might be a factor in preventing or treating issues caused by low brain GABA

[Press-News.org] Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified
Drug that targets the driver mutation proves effective in animal studies